Paratek Pharmaceuticals Analysis

Paratek Pharmaceuticals is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Paratek Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Paratek Pharmaceuticals is worth, separate from its market price. There are two main types of Paratek Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Paratek Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Paratek Stock Analysis Notes

About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.11. Paratek Pharmaceuticals last dividend was issued on the 31st of October 2014. The entity had 1:12 split on the 31st of October 2014. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. To find out more about Paratek Pharmaceuticals contact FACC FAHA at 617 807 6600 or learn more at https://paratekpharma.com.

Paratek Pharmaceuticals Investment Alerts

Paratek Pharmaceuticals is not yet fully synchronised with the market data
Paratek Pharmaceuticals has some characteristics of a very speculative penny stock
Paratek Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M.
Paratek Pharmaceuticals currently holds about 57.01 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03.
Roughly 55.0% of the company shares are owned by institutional investors

Paratek Pharmaceuticals Upcoming and Recent Events

2nd of November 2023
Upcoming Quarterly Report
View
21st of March 2024
Next Financial Report
View
30th of September 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of June 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Paratek Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 127.83 M.

Paratek Profitablity

The company has Profit Margin (PM) of (0.35) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25.

Paratek Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Paratek Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Paratek Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Paratek Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Paratek Pharmaceuticals Outstanding Bonds

Paratek Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Paratek Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Paratek bonds can be classified according to their maturity, which is the date when Paratek Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Paratek Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run My Watchlist Analysis Now

   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Transaction History
View history of all your transactions and understand their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stocks Directory
Find actively traded stocks across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences